TY - JOUR
KW - Adult
KW - Buprenorphine/therapeutic use
KW - Cocaine-Related Disorders/complications/psychology
KW - Community Health Services/trends
KW - Ethnic Groups
KW - Female
KW - Health Personnel
KW - Homeless Persons
KW - Humans
KW - Male
KW - Middle Aged
KW - Narcotics/therapeutic use
KW - Opioid-Related Disorders/rehabilitation
KW - Patient Compliance
KW - Pilot Projects
KW - Poverty
KW - Public Health Practice
KW - San Francisco
KW - Social Support
KW - Socioeconomic Factors
KW - Substance Abuse Detection
KW - Substance Abuse Treatment Centers/organization & administration/trends
KW - Treatment Outcome
AU - D. Hersh
AU - S. L. Little
AU - A. Gleghorn
A1 - 
AB - Despite well-documented efficacy, US physicians have been relatively slow to embrace the use of buprenorphine for the treatment of opioid dependence. In order to introduce and support the use of buprenorphine across the San Francisco Department of Public Health system of care, the Buprenorphine Pilot Program was initiated in 2003. Program treatment sites included a centralized buprenorphine induction clinic and program pharmacy, and three community-based treatment sites; two primary care clinics and a private dual diagnosis group practice. The target patient population consisted of opioid-dependent patients typically seen in an urban, public health setting, including individuals experiencing extreme poverty, homelessness/unstable housing, unemployment, polysubstance abuse/dependence, coexisting mental health disorders, and/or little psychosocial support. This program evaluation reviews patient characteristics, treatment retention, substance use over time, patient impressions, and provider practices for the 57 patients admitted between 9/1/03 and 8/31/05. At baseline, over 80% of patients were injecting heroin, over 40% were homeless, and over one-third were using cocaine. Outcomes included an overall one-year retention rate of 61%, a rapid and dramatic decline in opioid use, very positive patient impressions of the program and of buprenorphine, and significant shifts in provider practices over time.
BT - Journal of psychoactive drugs
C5 - Opioids & Substance Use; Education & Workforce; Healthcare Disparities
CP - 2
CY - United States
DO - 10.1080/02791072.2011.587704
IS - 2
JF - Journal of psychoactive drugs
N2 - Despite well-documented efficacy, US physicians have been relatively slow to embrace the use of buprenorphine for the treatment of opioid dependence. In order to introduce and support the use of buprenorphine across the San Francisco Department of Public Health system of care, the Buprenorphine Pilot Program was initiated in 2003. Program treatment sites included a centralized buprenorphine induction clinic and program pharmacy, and three community-based treatment sites; two primary care clinics and a private dual diagnosis group practice. The target patient population consisted of opioid-dependent patients typically seen in an urban, public health setting, including individuals experiencing extreme poverty, homelessness/unstable housing, unemployment, polysubstance abuse/dependence, coexisting mental health disorders, and/or little psychosocial support. This program evaluation reviews patient characteristics, treatment retention, substance use over time, patient impressions, and provider practices for the 57 patients admitted between 9/1/03 and 8/31/05. At baseline, over 80% of patients were injecting heroin, over 40% were homeless, and over one-third were using cocaine. Outcomes included an overall one-year retention rate of 61%, a rapid and dramatic decline in opioid use, very positive patient impressions of the program and of buprenorphine, and significant shifts in provider practices over time.
PP - United States
PY - 2011
SN - 0279-1072; 0279-1072
SP - 136
EP - 145
EP - 
T1 - Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program
T2 - Journal of psychoactive drugs
TI - Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program
U1 - Opioids & Substance Use; Education & Workforce; Healthcare Disparities
U2 - 21858959
U3 - 10.1080/02791072.2011.587704
VL - 43
VO - 0279-1072; 0279-1072
Y1 - 2011
ER -